Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $165.00

Merck & Co., Inc. (NYSE:MRK) had its price target hoisted by JPMorgan Chase & Co. from $150.00 to $165.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other analysts have also issued reports about the stock. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a research report on Wednesday, August 12th. Guggenheim lifted their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. BMO Capital Markets upped their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, August 20th. TD Cowen increased their target price on Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, September 23rd. Finally, UBS Group increased their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Seventeen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $150.32.

Merck & Co., Inc. Trading Up 0.5%

NYSE:MRK opened at $142.66 on Monday. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock has a fifty day simple moving average of $143.34 and a 200-day simple moving average of $127.96. The company has a market capitalization of $351.96 billion, a PE ratio of 114.12, a price-to-earnings-growth ratio of 6.18 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the prior year, the company earned $2.13 EPS. The firm’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. Merck & Co., Inc.’s payout ratio is 272.00%.

Insiders Place Their Bets

In related news, EVP Richard Deluca sold 20,784 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the transaction, the executive vice president owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after buying an additional 1,073,507 shares during the period. State Street Corp grew its holdings in Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after buying an additional 1,087,583 shares during the period. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the period. Bank of America Corp DE increased its stake in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Merck & Co., Inc. by 3.5% during the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock valued at $2,162,691,000 after acquiring an additional 701,249 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst remains bullish: Morgan Stanley lowered its price target modestly to $177 from $179 but maintained an “overweight” rating, implying substantial upside from recent levels. Morgan Stanley price target update
• Positive Sentiment: Long-term growth case intact: Analysts describe Merck’s recent pullback as a potential buying opportunity, citing continued Keytruda growth and new products and pipeline assets that could support the business after 2028. Merck Stock Down 7% in a Month
• Neutral Sentiment: Market-related gains: MRK recently outperformed the broader market during a positive trading session, but the move appeared tied more to overall market strength than to a new company-specific catalyst. Merck Beats Stock Market Upswing
• Neutral Sentiment: Analyst consensus: Sell-side analysts rate Merck a “Moderate Buy,” indicating that expected growth and valuation support the stock despite near-term risks. Merck Rated Moderate Buy
• Negative Sentiment: European Keytruda setback: A Dutch court granted Halozyme Therapeutics an injunction barring Merck from selling subcutaneous, or injectable, Keytruda in eight European markets. The ruling raises patent, launch-timing and revenue risks for Merck’s planned formulation, while benefiting Halozyme. Merck’s Injectable Keytruda Barred in Europe

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.